Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Criteria:

• Hemoglobin >= 9 g/dL
• Histologically or cytologically confirmed squamous cell carcinoma of the head and neck:
• Recurrent and/or metastatic disease
• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques OR as >= 10 mm with spiral CT scan
• No known brain metastases
• Life expectancy >= 2 months
• ECOG performance status (PS) 0-1 or Karnofsky PS 70-100% (for patients in cohort A)
• ECOG PS 2 or Karnofsky PS 60-70% (for patients in cohort B)
• WBC >= 3,000/mm^3
• Absolute neutrophil count >= 1,500/mm^3
• Platelet count >= 100,000/mm^3
• Calcium = = 60 mL/min
• QTc = 3 beats in a row)
• No history of other significant ECG abnormalities
• No uncontrolled hypertension (defined as systolic blood pressure [BP] >= 140 mm Hg or diastolic BP >= 90 mm Hg)
• No condition resulting in an inability to take oral medication, including any of the following:
• Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
• Active peptic ulcer disease
• No gastrostomy, jejunostomy, or other forms of enteral tube-feeding modalities
• No serious or nonhealing wound, ulcer, or bone fracture
• No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
• No cerebrovascular accident or transient ischemic attack within the past 12 months
• No myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within the past 12 months
• No pulmonary embolism within the past 12 months
• No pre-existing uncontrolled thyroid abnormality (i.e., inability to maintain thyroid function within the normal range with medication)
• No uncontrolled intercurrent illness, including either of the following:
• Ongoing or active infection
• Psychiatric illness or social situation that would limit compliance with study requirement
• No more than two prior regimens for recurrent or metastatic disease:
• Prior chemotherapy as part of initial curative intent therapy (e.g., neoadjuvant, adjuvant, or concurrent chemoradiotherapy) is allowed and will not count as prior therapy for recurrent or metastatic disease
• At least 4 weeks since prior major surgery
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
• At least 4 weeks since prior radiotherapy
• No prior treatment with any other antiangiogenic agent (e.g., bevacizumab, sorafenib, pazopanib, AZD2171, vatalanib, or VEGF Trap)
• No prior surgical procedure affecting absorption
• At least 7 days since prior and no concurrent use of CYP3A4 inhibitors, including any of the following:
• Azole antifungals (e.g., ketoconazole, itraconazole)
• Verapamil
• Clarithromycin
• HIV protease inhibitors (e.g., indinavir, saquinavir, ritonavir, atazanavir, nelfinavir)
• Erythromycin
• Delavirdine
• Diltiazem
• At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the following:
• Rifampin
• Phenytoin
• Rifabutin
• Hypericum perforatum (St. John's wort)
• Carbamazepine
• Efavirenz
• Phenobarbital
• Tipranavir
• No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin):

Concurrent dosing of =< 2 mg of warfarin daily for prophylaxis of thrombosis is allowed; Concurrent low molecular weight heparin allowed provided prothrombin time INR is =< 1.5

• No other concurrent investigational agents
• No concurrent agents with proarrhythmic potential, including any of the following:
• Terfenadine
• Quinidine
• Procainamide
• Disopyramide
• Sotalol
• Probucol
• Bepridil
• Haloperidol
• Risperidone
• Indapamide
• Flecainide
• No other concurrent anticancer agents or therapies
• No concurrent combination antiretroviral therapy for HIV-positive patients